Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Griggs

Showing results (251-260 of 257) with videos related to

Pageof 26
Sort By:
You have reached the last page of results.This site can display upto 257 results.
JCO Clinical Cancer Informatics|February 14, 2025
Methodologic Approach to Defining Comorbidities in a Cohort of Patients With Cancer: An Example in the Optimal Breast Cancer Chemotherapy Dosing StudyPeng Wang, Kelli O'Connell, Jenna Bhimani, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|July 25, 2024
Patient Characteristics Associated with Intended Nonguideline Chemotherapy in Women with Stage I to IIIA Breast CancerJenna Bhimani, Kelli O'Connell, Sonia Persaud, et al.
Breast Cancer Research and Treatment|August 16, 2024
The landscape of use of NCCN-guideline chemotherapy regimens in stage I-IIIA breast cancer in an integrated healthcare delivery systemJenna Bhimani, Kelli O'Connell, Sonia Persaud, et al.
JCO Oncology Practice|December 11, 2025
Clinician- and Facility-Level Factors Associated With Receipt of Nonguideline Chemotherapy Regimens in Women With Stage I-IIIA Breast CancerYashasvini Sampathkumar, Ziad Zakaria, Kelli O'Connell, et al.
Journal of the National Cancer Institute|March 5, 2026
Clinician- and facility-level factors associated with chemotherapy dose reductions in stages I-IIIA breast cancerYashasvini Sampathkumar, Ziad Zakaria, Kelli O'Connell, et al.
International Journal of Cancer|November 28, 2025
Evaluation of methods to identify chemotherapy-related hematologic toxicities in real-world settingsPeng Wang, Kelli O'Connell, Jenna Bhimani, et al.
Cancer|February 24, 2026
Initial chemotherapy dose reductions and subsequent treatment delivery in stage I-IIIA breast cancerMaria J Monroy-Iglesias, Kelli O'Connell, Jenna Bhimani, et al.
Pageof 26

Showing results (251-260 of 257) with videos related to

Sort By:
Pageof 26
You have reached the last page of results.This site can display upto 257 results.
JCO Clinical Cancer Informatics|February 14, 2025
Methodologic Approach to Defining Comorbidities in a Cohort of Patients With Cancer: An Example in the Optimal Breast Cancer Chemotherapy Dosing StudyPeng Wang, Kelli O'Connell, Jenna Bhimani, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|July 25, 2024
Patient Characteristics Associated with Intended Nonguideline Chemotherapy in Women with Stage I to IIIA Breast CancerJenna Bhimani, Kelli O'Connell, Sonia Persaud, et al.
Breast Cancer Research and Treatment|August 16, 2024
The landscape of use of NCCN-guideline chemotherapy regimens in stage I-IIIA breast cancer in an integrated healthcare delivery systemJenna Bhimani, Kelli O'Connell, Sonia Persaud, et al.
JCO Oncology Practice|December 11, 2025
Clinician- and Facility-Level Factors Associated With Receipt of Nonguideline Chemotherapy Regimens in Women With Stage I-IIIA Breast CancerYashasvini Sampathkumar, Ziad Zakaria, Kelli O'Connell, et al.
Journal of the National Cancer Institute|March 5, 2026
Clinician- and facility-level factors associated with chemotherapy dose reductions in stages I-IIIA breast cancerYashasvini Sampathkumar, Ziad Zakaria, Kelli O'Connell, et al.
International Journal of Cancer|November 28, 2025
Evaluation of methods to identify chemotherapy-related hematologic toxicities in real-world settingsPeng Wang, Kelli O'Connell, Jenna Bhimani, et al.
Cancer|February 24, 2026
Initial chemotherapy dose reductions and subsequent treatment delivery in stage I-IIIA breast cancerMaria J Monroy-Iglesias, Kelli O'Connell, Jenna Bhimani, et al.
Pageof 26